GTB-3650 is a TriKE therapeutic agent specifically targeting CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The product is designed to engage the patient’s immune cells to more effectively target and kill cancer cells, thereby enhancing the therapeutic prospects for patients with challenging forms of blood cancer.